REKENVY\u00ae Subcutaneous 250mg Pen launched in Japan. A self-administrable SC formulation delivered as two pens once weekly (total 500mg). The launch expands options beyond IV administration, enabling at-home or on-the-go self-administration and is expected to lower barriers to treatment initiation and continuation. Impact on FY March 2027 financial guidance is described as minimal.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4523","jir_company_name":"Eisai Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4523-20261113-01.pdf","jir_short_summary":"REKENVY\u00ae Subcutaneous 250mg Pen launched in Japan. A self-administrable SC formulation delivered as two pens once weekly (total 500mg). The launch expands options beyond IV administration, enabling at-home or on-the-go self-administration and is expected to lower barriers to treatment initiation and continuation. Impact on FY March 2027 financial guidance is described as minimal.","jir_summary":"### Overview of New Drug Launch\nEisai Co., Ltd., co-developer with Biogen, has launched the subcutaneous formulation of the anti-amyloid beta protofibril antibody REKENVY, the REKENVY Subcutaneous 250mg Pen, in Japan. Administered as 500mg once weekly using an autoinjector format that allows for self-administration. In addition to in-clinic IV administration, at-home and on-the-go self-administration become available options. The launch is expected to improve convenience and flexibility of treatment and reduce the burden associated with initiation and continuation of therapy.\n\n### Safety, Indications and Market Outlook\nSelf-administration should be performed under a physician's supervision as a general principle. Appropriate assessment and training are required for its use. Lecanemab is an antibody targeting A\u03b2 and protofibrils and has been approved in Japan for early AD. SC administration is suggested to provide efficacy comparable to IV administration, and the convenience of SC dosing is likely to reduce the outpatient burden for patients and caregivers. In the long term, efficiencies in the AD treatment pathway are expected.","jir_financial_highlights":"Drug Price: Unknown (Unknown)\nNew Launch: Unknown (Unknown)","jir_category":"","jir_hashtags":"#Eisai, #REKENVYSubcutaneous250mgPen, #AtHomeAdministration, #AlzheimersDiseaseTreatment","jir_key_figures":"Launch of lecanemab subcutaneous 250mg pen\nTwo pens once weekly (total 500mg) dosing\nEnables at-home administration (self-administration)","jir_meta_title":"Eisai Co., Ltd. Launches REKENVY Subcutaneous 250mg Pen in Japan | New At-Home Administration Option","jir_meta_description":"Eisai Co., Ltd. and Biogen have launched the anti-amyloid beta therapy REKENVY Subcutaneous 250mg Pen in Japan. Administered as 500mg once weekly, it enables at-home self-administration. Impact on FY March 2027 guidance is described as minimal.","jir_og_title":"Eisai Co., Ltd. Launches REKENVY Subcutaneous 250mg Pen in Japan | At-Home Administration Now Available","jir_og_description":"The REKENVY Subcutaneous 250mg Pen, newly launched in Japan, is administered as 500mg once weekly. Self-administration is possible and may reduce outpatient burden. Impact on FY March 2027 is described as minimal.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7482,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"product_announcement","footnotes":""},"sector":[],"importance":[],"class_list":["post-150903","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n